Cassava Sciences ( (SAVA) ) has released its Q1 earnings. Here is a breakdown of the information Cassava Sciences presented to its investors.
Cassava Sciences, Inc. is a clinical-stage biotechnology company based in Austin, Texas, focused on developing novel treatments for central nervous system disorders, including simufilam for tuberous sclerosis complex-related epilepsy.
In its latest earnings report, Cassava Sciences announced a strategic shift towards developing simufilam for TSC-related epilepsy, following the discontinuation of its Alzheimer’s disease program. The company also highlighted recent leadership appointments and a license agreement with Yale University as pivotal steps in advancing its new therapeutic focus.
Key financial metrics from the first quarter of 2025 include $117.3 million in cash and cash equivalents, with a net loss of $23.4 million, contrasting with a net income of $25.0 million in the same period last year. The decrease in R&D expenses by 16% was primarily due to the cessation of Alzheimer’s trials, while G&A expenses rose significantly due to legal costs.
Cassava Sciences is poised to initiate clinical trials for simufilam in TSC-related epilepsy by the first half of 2026, supported by a strong financial position and strategic collaborations. The company remains committed to its mission of developing innovative CNS treatments while managing expenses strategically.
Looking ahead, Cassava Sciences aims to leverage its enhanced team and favorable balance sheet to advance its pipeline, with a focus on simufilam’s potential in treating TSC-related epilepsy and other CNS disorders.